B+
Bull case
20%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
IMRX
ImmuneeringBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.8
Score
AI commentary
The company-source tone is operationally positive, but the T+3 follow-up remains low-conviction: consensus, analyst revisions, and post-release price reaction are unavailable, while social coverage is absent. The deterministic prior remains modestly negative over 20-120 days.
RankAlpha Sentiment Codex - 2026-08-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-15eventMAPKeeper 301 Phase 3 execution is now underwayHigh impact
The August 5 update confirmed patients are being dosed in the pivotal MAPKeeper 301 trial, with more than 30 study locations posted. This is the clearest near-term operating validation, although no efficacy readout is available yet. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-05]
2026-11-15catalystThin coverage may limit post-earnings reratingMedium impact
The packet contains no reliable Q2 consensus comparison, analyst estimate revision, target change, or post-release price-reaction attribution. With low coverage, positive clinical updates may not translate into sustained near-term demand.
2027-08-17catalystPivotal overall-survival readout remains the value-defining binaryHigh impact
MAPKeeper 301 is a randomized Phase 3 trial comparing atebimetinib plus mGnP with standard GnP. Company investor materials indicate a topline readout is expected in mid-2028; the result remains highly uncertain because current efficacy evidence is from a single-arm Phase 2a study.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology